Provided by Tiger Trade Technology Pte. Ltd.

Royalty Pharma plc

57.16
-0.4700-0.82%
Post-market: 57.160.00000.00%19:30 EDT
Volume:2.23M
Turnover:127.83M
Market Cap:32.98B
PE:30.66
High:57.91
Open:57.64
Low:56.96
Close:57.63
52wk High:64.38
52wk Low:35.23
Shares:576.94M
Float Shares:392.53M
Volume Ratio:0.82
T/O Rate:0.57%
Dividend:0.91
Dividend Rate:1.59%
EPS(TTM):1.86
EPS(LYR):1.78
ROE:13.97%
ROA:5.09%
PB:4.83
PE(LYR):32.09

Loading ...

Jun 02, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 22, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 09, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 09, 2023

Major Issues Report

8-K - Current report
Mar 28, 2023

Major Issues Report

8-K - Current report
Mar 15, 2023

Major Issues Report

8-K - Current report
Feb 15, 2023

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 15, 2023

Major Issues Report

8-K - Current report
Feb 13, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 09, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 09, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 09, 2023

Major Issues Report

8-K - Current report
Dec 01, 2022

Major Issues Report

8-K - Current report
Nov 08, 2022

Major Issues Report

8-K - Current report
Nov 08, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Oct 04, 2022

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Oct 03, 2022

Major Issues Report

8-K - Current report
Aug 11, 2022

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Aug 04, 2022

Major Issues Report

8-K - Current report
Aug 04, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]